Wells Fargo
IKT icon

Wells Fargo’s Inhibikase Therapeutics IKT Stock Holding History

Wells Fargo’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68.1K Sell
40,531
-27,302
-40% -$48.5K ﹤0.01% 5310
2025
Q4 		$139K Buy
67,833
+22,088
+48% +$35.1K ﹤0.01% 5253
2025
Q3 		$74.1K Buy
45,745
+7,419
+19% +$12.9K ﹤0.01% 5444
2025
Q2 		$74.7K Buy
38,326
+38,159
+22,850% +$74.7K ﹤0.01% 5358
2025
Q1 		$366 Hold
167
– – ﹤0.01% 6290
2024
Q4 		$543 Hold
167
– – ﹤0.01% 6306
2024
Q3 		$217 Hold
167
– – ﹤0.01% 6223
2024
Q2 		$202 Sell
167
-40
-19% -$69 ﹤0.01% 6201
2024
Q1 		$447 Buy
207
+6
+3% +$13 ﹤0.01% 6304
2023
Q4 		$255 Sell
201
-31
-13% -$32 ﹤0.01% 6543
2023
Q3 		$322 Buy
232
+36
+18% +$81 ﹤0.01% 6459
2023
Q2 		$707 Buy
196
+4
+2% +$15 ﹤0.01% 6408
2023
Q1 		$759 Buy
192
+169
+735% +$705 ﹤0.01% 6452
2022
Q4 		$68 Buy
23
+1
+5% +$4 ﹤0.01% 6909
2022
Q3 		$0 Hold
22
– – ﹤0.01% 6963
2022
Q2 		$0 Buy
22
+2
+10% +$12 ﹤0.01% 7107
2022
Q1 		$0 Hold
20
– – ﹤0.01% 7400
2021
Q4 		$0 Hold
20
– – ﹤0.01% 7492
2021
Q3 		$0 Buy
20
+18
+900% +$243 ﹤0.01% 7218
2021
Q2 		$0 Hold
2
– – ﹤0.01% 7137
2021
Q1 		$0 Buy
+2
New +$81 ﹤0.01% 7098

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wells Fargo's IKT Position: Q1 2026 in Review

Wells Fargo reduced its Inhibikase Therapeutics (IKT) stake by 40% in Q1 2026, selling an estimated $48.5K and leaving 40,531 shares worth $68.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5310.

Wells Fargo first reported a position in IKT in Q1 2021 and has held it in 21 quarters since. The position peaked at $139K in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Wells Fargo held 40,531 shares of Inhibikase Therapeutics worth $68.1K as of Q1 2026.
  • Wells Fargo sold 27,302 Inhibikase Therapeutics shares in Q1 2026, an estimated $48.5K.
  • Inhibikase Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5310 holding.
  • Wells Fargo first reported a position in Inhibikase Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Wells Fargo's Inhibikase Therapeutics position peaked at $139K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.